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This study aimed to ascertain the underlying neuro-biochemical imbalances that exist in children with 
ADHD by assessing the plasma levels of dopamine, serotonin, norepinephrine, γ amino butyric acid 
(GABA) and glutamate. Moreover, it investigated the potential effects of PUFA and vitamins 
supplementation as an alternative therapy to modulate the levels of these neurotransmitters and the 
overall clinical status of ADHD patients. The study included 40 ADHD patients, aged 4-6 years. The 
diagnostic and statistical manual of mental disorders (DSM-5) test has been employed to diagnose 
patients with ADHD and the severity of symptoms was assessed using the Arabic version of Conners' 
Parent Rating Scale. Additionally, patients were assessed using the Arabic versions of Mini International 
Neuropsychiatric Interview for Children (M.I.N.I. Kid) and Stanford-Binet Intelligence Scale, 5
th
 Edition 
(SB5). Recruited patient received nutritional supplement of semi-solid diet containing 1000 mg PUFA 
with selected vitamins once daily for six months. The evaluation of ADHD symptoms and levels of 
neurotransmitters has been carried out at pre-/post-intervention stage. Post-nutrition intervention 
assessment, there was a significant increase in dopamine, norepinephrine, GABA levels (p-value < 
0.0001) with significant decrease in glutamate level (p-value < 0.0001) when compared to their 
correspondent pre-intervention levels. Symptoms of inattention and/or hyperactivity-impulsivity were 
significantly improved after 6 months nutrition intervention program (p-value<0.001). Therefore, 
supplementation with omega-3 fatty acids and vitamins could be considered more extensively in therapy 
of ADHD patients particularly those who are less than 6 years old 
Keywords: ADHD; Neurotransmitters; Dopamine; PUFA; Omega-3. semi-solid diet  
 
INTRODUCTION 
Attention-deficit hyperactivity disorder (ADHD) is a 
chronic neurodevelopmental disorder 
characterized by a persistent pattern of inattention 
and/or hyperactivity-impulsivity; it begins in 
childhood, and affects cognitive abilities, personal, 
familial and social interaction (American 
Psychiatric Association, 2013). Epidemiological 
studies indicate that ADHD is a prevalent disorder 
affecting between 6.7 to 7.8% of children 
worldwide (Thomas, et al., 2015). This prevalence 
is higher in Arabic speaking countries reaching 
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9.4% in Egypt (Bishry, et al., 2014) and 11.6% in 
Saudi Arabia (Homidi, et al., 2013). Based on 
family history, genotyping, and neuroimaging 
studies, there is clear evidence to support a 
biological basis for ADHD. Although multiple 
regions of the brain and several neurotransmitters 
have been implicated in the emergence of 
symptoms, dopamine continues to be a focus of 
investigation regarding ADHD symptoms (Sadock, 
et al., 2014). Inadequate levels of norepinephrine 
and dopamine in brain synapses have been 
implicated as a cause of ADHD symptoms 
(Dervola, et al., 2012). The disturbance in 
dopaminergic function is considered as a possible 
cause of ADHD that alters serotonergic and 
glutamatergic transmissions (Tripp, et al., 2012). 
Central nervous system stimulants are considered 
the first choice of treatment for ADHD as they 
have been shown to have the best efficacy. Non-
stimulant medications approved by the United 
States, Food and Drug Administration (FDA) in 
the treatment of ADHD include atomoxetine, a 
norepinephrine uptake inhibitor. Unlike the 
stimulants, atomoxetine carries with it a black box 
warning for potential increases in suicidal 
thoughts or behaviors and requires children with 
ADHD to be monitored for these symptoms. α-
agonists, clonidine and guanfacine, are also FDA 
approved for the treatment of ADHD, but for 
patients aged 6 years and older. Moreover, the 
UK National Institute for Health and Care 
Excellence(NICE) guidelines does not 
recommend prescribing any of these medications 
in children younger than 6 years old (Sadock, et 
al, 2014). 
Cognitive abilities may be affected by deficient 
PUFA in the diet of children, and its 
supplementation to pregnant women may affect 
the offspring (Millichap and Yee, 2012), and 
potentially affect the prevalence of ADHD 
(Dopheide and Pliszka, 2009). Pre-and postnatal 
environmental factors play an important role in the 
pathogenesis of ADHD.  Under nutrition and 
dietary deficiency in ADHD patients has been 
proposed to be one of postnatal factors. An 
imbalance ratio between omega-3 and omega-6 
intake has been suggested to be involved in the 
development of ADHD (Raz and Gabis, 2009). 
Moreover, dietary supplementation with omega-3 
PUFA may enhance both synaptic development 
and function (Kim, et al, 2011). Gene 
transcription, neurotransmitter metabolism and 
activities of synaptic vesicles and transporters 
may be changed by different fatty acids in 
neurons and glia cells (Levant, et al, 2006). 
Several regulatory processes such as modification 
of cerebral receptors in certain brain areas were 
changed as a result of omega-3 PUFA deficiency 
as this leads to changes in the vesicular pool and 
synaptic levels of serotonin (5-HT) (Chalon, 
2006). Docosahexaenoic acid (DHA) –one of 
omega-3 fatty acids – promotes glutamatergic 
synaptic activities with subsequent increases in 
synapsin and glutamate receptor subunit 
expression in hippocampal neurons (Kim, et al., 
2011). As a result, spontaneous synaptic activity 
is significantly intensified. Deficient of DHA results 
in inhibition of synaptogenesis, decreases in 
synapsins and glutamate receptor subunits, and 
long-term potentiation of hippocampal neurons 
impairment (Cao, et al., 2009). 
Although role for brain neurotransmitters in the 
etiology of ADHD has been hypothesized for 
decades, yet measuring levels of 
neurotransmitters has received limited research 
attention, and to the best of our knowledge this is 
the first research studying the neurotransmitters’ 
status in Egyptian children (less than 6 years old) 
diagnosed with ADHD. This is an aspect of the 
problem which if highlighted may provide a better 
understanding of the psycho pathophysiology of 
patients with ADHD. Moreover, effectiveness of 
PUFA as treatment of ADHD is controversy. 
Results of different researchers studied 
effectiveness of PUFA are contradicted from 
studies showed that PUFA is as effective as 
stimulants to studies found that it causes no 
improvement at all in ADHD symptoms. Hence, 
the current study also aimed to investigate the 
potential effects of PUFA supplementation on 
levels of these neurotransmitters and to study the 
efficacy of PUFA coupled with vitamins 
supplementation in alleviating ADHD symptoms in 
children younger than 6 years old. 
 
MATERIALS AND METHODS 
Patients recruitment  
This pilot study recruited 40 children diagnosed 
with ADHD. They were selected from children with 
special needs clinic– National Research Centre 
NRC (Cairo, Egypt). A written informed consent 
was obtained from the guardians of the 
participants, according to the guidelines of the 
ethical committee of the National Research 
Centre, Cairo, Egypt (all experiments were 
approved by the Institution Ethical Review Board 
according to Helsinki Declaration 1964 revised in 
2013). ADHD patient with co-morbid psychiatric 
disorders, on treatment for ADHD, with below 
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average IQ of 70 or with chronic medical illness 
were excluded. 
Procedures 
1) At the beginning of the study (baseline), all 
patients were subjected to the following 
assessments (see Box 1): 
Full personal and medical history with thorough 
clinical examination. A three-generation family 
pedigree were constructed and analyzed to check 
for other affected family members. 
Clinical psychiatric interviewing: ADHD was 
diagnosed according to DSM-5(American 
Psychiatric Association, 2013). 
Mini International Neuropsychiatric Interview for 
Children (M.I.N.I. Kid) which is a short structured 
diagnostic interview for DSM-IV and ICD-10 
psychiatric disorders (Sheehan and Janavs, 
1998). This interview was employed to confirm 
ADHD diagnosis and to exclude other psychiatric 
co-morbidities. The Arabic version of M.I.N.I. Kid 
has been validated with satisfactory reliability and 
validity and has been used in many studies in 
Arab Countries (Ghanem, et al., 1999). 
IQ assessment using the Arabic version of 
Stanford-Binet Intelligence Scale, 5
th
 Edition 
(SB5) has been employed (Farag, 2011) to 
exclude children with below average IQ (70). 
2) ADHD patient were further assessed using the 
Arabic version of Conners' Parent Rating Scale-
Revised; Long Version (CPRS-R-L) to assess the 
severity of ADHD symptoms (Conners, 1997; El-
Sheikh, et al, 2003).  
3) At the end of study period the ADHD patients 
were assessed using CPRS-R-L to assess the 
response to treatment. 
4) Laboratory investigations:  
Plasma level of Serotonin (5‐HT) using the High-
Performance Liquid Chromatography (HPLC) 
method 
Plasma level of Norepinephrine (NE) using HPLC 
method 
Plasma level of Dopamine (DA) by HPLC method 
Plasma level of γ amino butyric acid (GABA) 
(ELISA) 
Plasma level of Glutamate (using colorimetric 
method)  
Levels of these neurotransmitters were re-
measured at the end of study period. 
Box 1: Summary of all pre- and post-intervention tests for ADHD patients 
Test ADHD patient 
 Pre-intervention Post-intervention 
Full personal and medical history with 
thorough clinical examination 
Yes - - 
DSM-5 Yes - - 
M.I.N.I. Kid) Yes - - 
IQ assessment Yes - - 
Conners' Parent Rating Scale-Revised Yes - - 
Long Version (CPRS-R-L) Yes Yes 
Laboratory tests   
Serotonin (5‐HT) Yes Yes 
Norepinephrine (NE) Yes Yes 
Dopamine (DA) Yes Yes 
γ amino butyric acid (GABA) Yes Yes 
Glutamate Yes Yes 
Box 2: Nutrition facts of major constituents of intervention meal (values are given per 100g SSDP 
weight) 
Macronutrients (g/100g) Micronutrients (g/100g) 
Total solids = 29.2g 








Fat = 15.5 g 
PUFA =3.1g 







Vitamin C 0.00798g 
Calories 263.1 kcal/100g 
Serving Size (50g) given once per day 
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HPLC operation conditions:  
The determination of norepinephrine, dopamine 
and serotonin was carried out using laboratory 
HPLC system, Agilent technologies 1100 series, 
equipped with a quaternary pump (Quat pump, 
G131A model). Separation was achieved on 
ODS-reversed phase column (C18, 25 x 0.46 cm 
internal diameter 5 μm). The mobile phase 
consisted of potassium phosphate 
buffer/methanol 97/3 (v/v) and was delivered at a 
flow rate of 1.5 ml/min. UV detection was 
performed at 270 nm, and the injection volume 
was 20 μl. The concentration of both 
catecholamines and serotonin were determined 
by external standard method using calculated 
peak areas. Serial dilutions of standards were 
injected, and their peak areas were derived. A 
linear standard curve has been constructed by 
plotting peak areas versus the corresponding 
concentrations. The concentration in samples was 
quantified from the curve. 
Nutritional intervention program 
Semi-solid dairy product (SSDP) was prepared 
from Buffalo’s milk retentate which contained 
29.2% total solids, 15.5 %, fat and 12 % total 
protein, in addition to 3.1% PUFA, essential 
minerals, vitamin A and vitamin C. Box-2 shows 
all actual values of minerals and vitamins of 
SSDP, including the total calorific value and total 
weight of the given semi-solid dairy product. 
Additionally, to their normal dietary intake each 
patient consumed 50g of SSDP on daily basis. 
SSDP has been supplemented to patients for the 
duration of six months during which the ADHD 
children were regularly followed up every two-
week interval in the clinic to provide them with the 
supplement, monitor intake and assess if any 
adverse effect that might emerge. At the end of 
these six months there was post intervention 
assessment of neurotransmitters to verify the 
impact post-nutritional intervention program. This 
was coupled with re-assessment of these children 
using Conners' Parent Rating Scale-Revised; 
Long Version. 
Statistical tests:  
SPSS computer package version 17 (SPSS, 
Chicago, IL, USA) has been employed to analyze 







 Table (1) showed the socio demographic 
data (age, sex, place of residence). 
Table (1): Socio-demographics of ADHD 
patients 
 
Family profile and family history:  
Regarding consanguinity 21.6% of parents of 
ADHD patients were first cousins.  
Levels of neurotransmitters in ADHD patients 
before and after supplementations: 
Comparison of plasma levels of 
neurotransmitters in ADHD patients before 
starting the supplements and at the end of study 
period reported statistical significant increase in 
levels of dopamine, norepinephrine and GABA 
associated with significant decrease in level of 
glutamate (table 2). 
Table (2): Neurotransmitters’ levels in ADHD 
patients before and after supplementation for 
six-month period (N=40) 
pg/ml: pictogram per milliliter. ng/ml: nanogram 
per milliliter 
μg/ml: microgram per milliliter. pmol /ml:picomol 
per milliliter 
*














Dopamine  (pg/ml) 7.641± .641 238.7 ± 43.6 0.00* 
Serotonin (ng/ml) 7.641± ..4. 160.4 ±69.43 0.4 
Norepinephrine 
(pg/ml) 





GABA (pmol /ml) 133.1± 21.5 319.1± 18.2 0.00* 




male 28 (70%) 
female 12 (30%) 
Age 
mean± SD 5.1± 1.2 
  
Residency 
urban 35 (89.2%) 
rural 5 (10.8%) 
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Severity of ADHD symptoms in patients post-
supplementation (six-month intervention): 
Comparison of severity of ADHD symptoms 
pre-and post-supplementation revealed 
statistically significant improvement on the 
inattention, DSM-IV: inattentive, DSM-IV: total and 
Conners' ADHD, restless-impulsive and emotional 




Figure (1): Severity of ADHD symptoms, as assessed by Conners' Parent Rating Scale, before and 
after supplements.  
There was statistically significant improvement on the inattention (p value= 0.001), DSM-IV: 
inattentive (p value= 0.000), DSM-IV: total (p value= 0.003) and Conners' ADHD (p value= 0.000), 
restless-impulsive (p value= 0.02) and emotional lability (p value= 0.018) indices 
 
Table (3): Severity of ADHD symptoms as assessed by CPRS-R-L before and after supplements 
Conner's parents 
 rating scale 
Patients before treatment Patients after treatment P value 
Mean SD Mean SD 
Opposition 60.09 10.8 62.7 11.2 0.43 
Inattention 76.3 11.201 72.03 14.44 0.001
* 
Hyperactivity 79.83 13.641 76.73 12.01 0.189 
Anxiety-Shyness 47.2 2.5 46 1.6 0.25 
Perfectionism 66.83 13.081 67.3 10.31 0.84 
Social problems 56.55 10.40 51.82 9.93 0.076 
Psychosomatic 71.2 18.874 73 13.85 0.565 
Conners' ADHD index 76.73 9.172 71.43 11.78 0.000
* 
Conners'index:Restless-Impulsive 77.97 10.07 72.27 13.47 0.02
* 
Conners' index: Emotional lability 75.87 12.564 70.73 15.32 0.018
* 
Conners' index: total 77.87 11.1 73.77 14.31 0.07 
DSM-IV: Inattentive 76.83 10.185 73.03 12.99 0.000
* 
DSM-IV:Hyperactivity-Impulsive 80.53 11.331 76.93 9.738 0.058 
DSM-IV: Total 81.07 8.61 77.27 11.7 0.003
* 
*










90 symptoms before supplements symptoms after supplements
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and emotional lability indices, DSM-IV: inattentive and DSM-IV: total of the Conner's parents rating scale 
in the ADHD patients before and after the 6-months nutritional program as p ≤ 0.05. 
 
DISCUSSION 
In this study, role of genetic factor has been 
investigated, 21.6% of parents of ADHD patients 
were first cousins. Delivery by cesarean section 
was 40.5% of ADHD patients. This finding is 
consistent with the literature However, Tian et al., 
(2009) had concluded that cesarean section itself 
had no significant impact on attentiveness in 
school children, while medical indications for 
cesarean section may have contributed to a major 
cause of ADHD (Tian, et al., 2009). 
Supplementation with Omega-3 Fatty acids 
The supplementation with PUFAs in childhood 
has a pivotal role for the functioning and 
development of the brain (Borsonelo and 
Galduróz, 2008), as the docosahexaenoic (DHA) 
and arachidonic acid (AA), accumulate rapidly in 
the gray matter of the brain during early childhood 
(Wainwright, 2002), their deficiency may lead to 
irreversible memory, learning, mood and sensorial 
system deficits (Yehuda, et al., 2005).  
The present study indicated a possible 
improvement in the symptomatology of the ADHD, 
and showed statistical significant improvement in 
the following Conner’s parents rating scale 
subscales; inattention, DSM-IV: inattentive, DSM-
IV: total and Conners' ADHD, restless-impulsive 
and emotional lability indices after nutritional 
supplementation (1000 mg PUFA once daily for 
six months intervention), this is consistent with 
Germano et al.. (2007) 
A diet deficient inomega-3 may influence 
neurotransmission, the dopaminergic and the 
serotonergic systems, which lead to reduction of 
dopamine (Chalon, 2006). The increase in the 
ingestion of omega-3 may promote the central 
activity of dopamine in the pre-frontal cortex, thus 
deceasing aggressiveness and impulsiveness 
(Chalon et al., 2001). 
Plasma level of neurotransmitters: 
This study showed significant increase in 
norepinephrine and dopamine levels (p=0.001) 
and slight non-significant increase (p=0.4) in 
serotonin level pre- and post-nutritional 
intervention program. 
The diet, chronic stress, nutritional deficiencies 
and environmental toxins were considered as 
primary risk factors for imbalance or depletion of 
neurotransmitters, but also genetic polymorphism 
may prevent the formation of certain 
neurotransmitters (Borsonelo and Galduróz, 
2008). 
The excitatory neurotransmitter glutamate 
implicated, in the pathophysiology of ADHD, due 
to its interaction with dopamine and 
norepinephrine (Lesch, et al, 2013) and 
imbalances in glutamate may interfere with the 
gating of sensory information in striato-frontal 
pathways in those patients. 
Deficits in omega-3 fatty acids have been linked to 
many neurodevelopmental problems including 
ADHD, and its deficiency causes hyperactivity or 
lack of attention. ADHD children have reduced red 
blood cell omega-3 fatty acids compared to 
typically developing children. Deficits in dietary 
omega-3 fatty acid have also been linked to 
alterations in glutamatergic and serotoninergic 
neurotransmission, as well as mesocortical and 
mesolimbic dopaminergic system dysfunction 
(Borsonelo and Galduróz, 2008). Inflammatory 
mechanisms have been proposed to be possible 
factors in ADHD (Buske-Kirschbaum, et al., 2013). 
Nonetheless, PUFA has anti-inflammatory 
actions, so it can prevent inflammation in 
astrocytes (Singh, et al., 2012). It also influences 
genetic transcription, signal transduction (Haag, et 
al, 2003), and the fluidity of membranes, since the 




 ATPase is 
influenced by the fatty acid composition of the 
membrane these mechanisms may clarify 
glutamate uptake regulation (Gerbi, et al., 1999). 
The reduction in GABA levels is accompanied 
with less cognitive control, impaired response 
inhibition and high impulsivity (Silveri, et al., 
2013). In the present study the results showed 
significant increase in GABA (the main inhibitory 
neurotransmitter) level when compared to its level 
before intervention, on the other hand there was a 
significant decrease in glutamate level (p- 
value<0.05) as a result of the nutritional 
intervention program,. 
CONCLUSION 
In conclusion, healthy and balanced nutrition 
should be encouraged among children who are 6 
years old and living with ADHD. While 
pharmacological therapy has proven to be 
efficacious in controlling disruptive behavior and 
inattention in those patients; however, it is not 
recommended for children younger than 6 years 
old. In this study, nutritional supplementation with 
omega-3 fatty acids and selected vitamins 
appeared to be effective in alleviating ADHD 
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symptoms especially the cognitive problems and 
inattention in less than 6 years old children. 
Moreover, omega-3 and vitamins supplementation 
induces increase in plasma levels of dopamine, 
norepinephrine and GABA and as well as 
decrease in level of glutamate the excitatory 
neurotransmitter, so it should be considered more 
extensively in the management of ADHD patients, 
in particular this studied cohort. 
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